Andere talen SyntekaBio, Inc.

Aandelen

A226330

KR7226330009

Software

Slotkoers Korea S.E. Andere beurzen 07-02-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8.250,00 ^KRW	-4,07%		+14,58%	+57,14%

10/09	SyntekaBio, Inc. benoemt Joonhyuk Choi tot hoofd van de Amerikaanse activiteiten	CI
20/06	Syntekabio ondertekent intentieverklaring met bioSeedin	CI

Andere talen

SyntekaBio, Inc.(KOSDAQ:A226330) dropped from S&P Global BMI Index	23-09-24
SyntekaBio, Inc. Appoints Joonhyuk Choi as Head of US Operations	10-09-24
Syntekabio Signs Memorandum of Understanding with the bioSeedin	20-06-24
SyntekaBio, Inc. signed Memorandum of Understanding to acquire bioSeedin from Acrobiosystems Co.,Ltd..	20-06-24
Syntekabio to Showcase Advanced AI Drug Discovery Technologies at BIO International Convention 2024	23-05-24
Syntekabio Announces to Showcase Biologics Discovery Platform At PEGS Boston	07-05-24
SyntekaBio, Inc. announced that it has received KRW 10 billion in funding from Korea Investment Partners Co. Ltd.	26-04-24
Syntekabio to Showcase Innovative AI Drug Discovery Technologies at Bio-IT World	11-04-24
SyntekaBio, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Investment Partners Co. Ltd.	28-03-24
Polarisqb and Syntekabio Sign MOU for Collaborative AI and Quantum-Pored Drug Development Service	31-08-23
SyntekaBio, Inc. announced that it has received KRW 10 billion in funding	28-07-23
SyntekaBio, Inc. announced that it expects to receive KRW 10 billion in funding	21-07-23
Syntekabio Announces the Launch of its Cost-Effective AI-Based Total Solution Service for Finding New Drug Candidates	03-06-23
SyntekaBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23
Syntekabio, Inc. Launches STB Cloud Worldwide	16-12-22
Advanced AI Drug Development Platform 'DeepMatcher' 2.0 Launches Worldwide (226330.KQ)	22-09-22
Advanced AI Drug Development Platform 'DeepMatcher®' 2.0 Launches Worldwide (226330.KQ)	21-09-22
SyntekaBio, Inc. announced that it has received KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation,KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors	30-11-21
SyntekaBio, Inc. announced that it expects to receive KRW 25 billion in funding from Shinhan Financial Investment Co., Ltd., Saneun Capital Co., Ltd., Best Investment & Securities Co., Ltd., IBK Capital Corporation, KDB Capital Corp., Shinhan Investment Corp., Investment Arm and other investors	25-11-21
SyntekaBio, Inc.(KOSDAQ:A226330) added to S&P Global BMI Index	21-09-20
Syntekabio Presents Nonclinical Data of Immuno-Oncologic Agent Stb-C017 At the 2020 AACR Meeting	15-05-20
SyntekaBio, Inc. has completed an IPO in the amount of KRW 19.2 billion.	12-12-19
Syntekabio Enters into Agreement with CHA Hospital	06-12-19
SyntekaBio, Inc. has filed an IPO.	26-08-19
Syntekabio, Inc. announced that it has received KRW 19.69994646 billion in funding from a group of investors	21-06-19

Word de lid om toegang te krijgen tot meer nieuws.

Gratis inschrijven

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SyntekaBio, Inc.

Aandelen

A226330

KR7226330009

Software

Andere talen

Filters